Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Financial Statements Detail

v3.7.0.1
Condensed Consolidated Financial Statements Detail
3 Months Ended
Mar. 31, 2017
Condensed Consolidated Financial Statements Detail [Abstract]  
Condensed Consolidated Financial Statements Detail

3. Condensed Consolidated Financial Statements Detail

Cash and Cash Equivalents

As of March 31, 2017, cash and cash equivalents consisted of demand deposits of $2.9 million and money market funds of $17.2 million with maturities of less than 90 days at the date of purchase. As of December 31, 2016, cash and cash equivalents consisted of demand deposits of $21.5 million and money market funds of $4.2 million with maturities of less than 90 days at the date of purchase.

Property and Equipment, net

Property and equipment, net consisted of the following (in thousands):

 

 

March 31,

 

 

December 31,

 

 

 

2017

 

 

2016

 

Equipment and furniture

 

$

2,691

 

 

$

14,023

 

Leasehold improvements

 

 

554

 

 

 

554

 

 

 

 

3,245

 

 

 

14,577

 

Less: Accumulated depreciation and amortization

 

 

(2,849

)

 

 

(13,541

)

Property and equipment, net

 

$

396

 

 

$

1,036

 

During the three months ended March 31, 2017, the Company completed the sale of equipment located in one of its leased facilities for total proceeds of $1.6 million. Of the $1.6 million, $0.8 million is included in other receivables as of March 31, 2017. The carrying value of the equipment sold was $0.3 million. Accordingly, the Company recorded a gain of $1.3 million on the sale of equipment in the other income (expense), net line of the condensed consolidated statement of comprehensive loss.

 

Accrued and Other Liabilities  

Accrued and other liabilities consisted of the following (in thousands):

 

 

March 31,

 

 

December 31,

 

 

 

2017

 

 

2016

 

Accrued payroll and other benefits

 

$

123

 

 

$

1,582

 

Accrued clinical trial costs

 

 

394

 

 

 

743

 

Accrued incentive compensation

 

 

203

 

 

 

 

Accrued legal and accounting fees

 

 

670

 

 

 

385

 

Other

 

 

783

 

 

 

1,505

 

Total

 

$

2,173

 

 

$

4,215

 

 

Net Loss Per Share Available to Common Stockholders

The following is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the calculation of basic and diluted net loss per share available to common stockholders (in thousands):

 

 

Three Months Ended March 31,

 

 

 

2017

 

 

2016

 

Numerator

 

 

 

 

 

 

 

 

Net loss

 

$

(10,715

)

 

$

(8,365

)

Deemed dividend on convertible preferred stock

 

 

(5,603

)

 

 

 

Net loss available to common stockholders, basic and diluted

 

$

(16,318

)

 

$

(8,365

)

 

 

 

 

 

 

 

 

 

Denominator

 

 

 

 

 

 

 

 

Weighted average shares outstanding used for basic and diluted net loss per share available to common stockholders

 

 

6,887

 

 

 

5,978

 

Potentially dilutive securities are excluded from the calculation of diluted net loss per share available to common stockholders if their inclusion is anti-dilutive. The following table shows the weighted-average outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share available to common stockholders (in thousands):

 

 

Three Months Ended March 31,

 

 

 

2017

 

 

2016

 

Convertible preferred stock (as converted)

 

 

2,446

 

 

 

 

Common stock options and RSUs

 

 

653

 

 

 

535

 

Warrants for common stock

 

 

381

 

 

 

911

 

Total

 

 

3,480

 

 

 

1,446